The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Targeted therapies and immunotherapies are associated with a wide range of dermatologic
adverse events (dAEs) resulting from common signaling pathways involved in malignant …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

Flavonoid-containing food supplements are widely used as antioxidants, and the continuous
use of these supplements with other drugs can lead to clinically significant interactions …

Patients treated with systemic anticancer drugs often show changes to their nails, which are
usually well tolerated and disappear on cessation of treatment. However, some nail toxicities …

Highlights•This ESMO Clinical Practice Guideline provides recommendations on the
prevention/management of dermatological toxicities.•Authorship includes a multidisciplinary …

The interaction between erlotinib (ERL) and bovine serum albumin (BSA) was studied in the
presence of quercetin (QUR), a flavonoid with antioxidant properties. Ligands bind to the …

Many researchers are attempting to identify drugs that can be repurposed as effective
therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal …

The current study was aimed to prepare a molecular complex of erlotinib (ERL) with
phospholipid (PC) for enhancement of solubility and thus bioavailability, therapeutic efficacy …

Background Afatinib has shown long progression free survival and improvement in quality of
life in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Although afatinib causes …